Thompson Siegel & Walmsley LLC Sells 83,227 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Thompson Siegel & Walmsley LLC lowered its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 21.3% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 306,793 shares of the medical research company's stock after selling 83,227 shares during the period. Bio-Rad Laboratories makes up approximately 1.5% of Thompson Siegel & Walmsley LLC's portfolio, making the stock its 11th biggest holding. Thompson Siegel & Walmsley LLC owned about 1.10% of Bio-Rad Laboratories worth $102,647,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Commerce Bank purchased a new stake in shares of Bio-Rad Laboratories in the third quarter valued at about $240,000. Avior Wealth Management LLC lifted its position in shares of Bio-Rad Laboratories by 3.3% during the 3rd quarter. Avior Wealth Management LLC now owns 999 shares of the medical research company's stock worth $334,000 after buying an additional 32 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of Bio-Rad Laboratories by 10.0% in the 3rd quarter. PNC Financial Services Group Inc. now owns 8,755 shares of the medical research company's stock worth $2,929,000 after buying an additional 795 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG bought a new position in shares of Bio-Rad Laboratories in the third quarter valued at approximately $422,000. Finally, Mawer Investment Management Ltd. lifted its holdings in Bio-Rad Laboratories by 63.0% during the third quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company's stock worth $72,900,000 after acquiring an additional 84,237 shares during the period. 65.24% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, COO Andrew J. Last sold 3,000 shares of the company's stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $329.94, for a total value of $989,820.00. Following the transaction, the chief operating officer now owns 7,559 shares in the company, valued at $2,494,016.46. The trade was a 28.41 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP James Barry sold 623 shares of the firm's stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total transaction of $205,895.27. Following the sale, the executive vice president now owns 147 shares of the company's stock, valued at approximately $48,582.03. This represents a 80.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 17.06% of the stock is owned by corporate insiders.

Bio-Rad Laboratories Stock Up 0.7 %

BIO traded up $2.30 during trading on Thursday, reaching $325.99. The stock had a trading volume of 113,975 shares, compared to its average volume of 246,192. Bio-Rad Laboratories, Inc. has a one year low of $262.12 and a one year high of $387.99. The company has a quick ratio of 4.52, a current ratio of 6.14 and a debt-to-equity ratio of 0.16. The business has a 50-day moving average of $340.30 and a 200-day moving average of $315.25.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, topping analysts' consensus estimates of $1.16 by $0.85. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The firm had revenue of $649.70 million for the quarter, compared to analyst estimates of $628.18 million. During the same period last year, the company earned $2.33 EPS. The business's quarterly revenue was up 2.8% compared to the same quarter last year. As a group, analysts forecast that Bio-Rad Laboratories, Inc. will post 9.93 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on BIO shares. Citigroup lifted their target price on Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. StockNews.com upgraded shares of Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research note on Friday, November 1st. Royal Bank of Canada upped their price objective on Bio-Rad Laboratories from $446.00 to $469.00 and gave the company an "outperform" rating in a research note on Thursday, October 31st. Finally, Wells Fargo & Company started coverage on Bio-Rad Laboratories in a research report on Tuesday, August 27th. They issued an "equal weight" rating and a $340.00 target price for the company. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $391.80.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.